Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing molecular mechanisms and biomarker potential without primary human data or systematic review methods.
PubMed 25975510 · doi:10.1016/j.tins.2015.04.003
What was done
This narrative review summarizes the literature on glial fibrillary acidic protein (GFAP), focusing on its cellular distribution, intermediate filament assembly, transcriptional regulation, post-translational modifications, involvement in Alexander disease and astrogliosis, and release into biofluids following neurological injury.
What was found
The abstract reports no numerical data or quantitative metrics. It notes that GFAP expression is regulated by nuclear-receptor hormones, growth factors, and lipopolysaccharides; mutations cause Rosenthal fiber deposition in Alexander disease; gene activation drives astrogliosis; and GFAP and its breakdown products are rapidly released into biofluids following traumatic brain injury, spinal cord injury, and stroke.
Why it matters
The paper connects basic astrocyte intermediate filament biology to clinical diagnostics, establishing GFAP and its breakdown products as candidate fluid biomarkers for central nervous system trauma and neurodegeneration.
Limits
As a narrative review, the publication presents no primary experimental data, patient cohorts, or quantitative diagnostic performance metrics (such as sensitivity, specificity, or receiver operating characteristic values). Search criteria and study selection methods are not specified in the abstract.
Cited by
- supports Glial fibrillary acidic protein (GFAP) is an intermediate filament protein whose levels in blood elevate during reactive astrogliosis and brain inflammation.